Acute promyelocytic leukaemia with coagulopathy
APL / DIC · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A subtype of acute myeloid leukaemia presenting with life-threatening bleeding from DIC and hyperfibrinolysis. Early ATRA (all-trans retinoic acid) and aggressive blood-product support before genetic confirmation are life-saving.
Assessment
Investigations
- FBC + blood film (promyelocytes)
- Coagulation, fibrinogen, D-dimer (DIC)
- Urgent haematology and PML-RARA testing
Management
- Start ATRA urgently on clinical suspicion - do not wait for confirmation
- Aggressive product support: platelets, fibrinogen/cryoprecipitate, FFP
- Maintain fibrinogen and platelet targets
- Watch for differentiation (ATRA) syndrome
- Haematology; transfer to a treatment centre
Drugs & doses
ATRA (all-trans retinoic acid)
Platelets / cryoprecipitate / FFP
Disposition
Haematology centre.
Suspected APL with bleeding is an emergency - give ATRA and clot factors early, before molecular results return.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.